Show simple item record

dc.contributor.authorGottlieb, SL
dc.contributor.authorNdowa, F
dc.contributor.authorHook, EW
dc.contributor.authorDeal, C
dc.contributor.authorBachmann, L
dc.contributor.authorAbu-Raddad, L
dc.contributor.authorChen, XS
dc.contributor.authorJerse, A
dc.contributor.authorLow, N
dc.contributor.authorMacLennan, CA
dc.contributor.authorPetousis-Harris, H
dc.contributor.authorSeib, KL
dc.contributor.authorUnemo, M
dc.contributor.authorVincent, L
dc.contributor.authorGiersing, BK
dc.date.accessioned2020-07-17T01:25:13Z
dc.date.available2020-07-17T01:25:13Z
dc.date.issued2020
dc.identifier.issn0264-410X
dc.identifier.doi10.1016/j.vaccine.2020.02.073
dc.identifier.urihttp://hdl.handle.net/10072/395562
dc.description.abstractRenewed interest in developing vaccines against Neisseria gonorrhoeae has been sparked by the increasing threat of gonococcal antimicrobial resistance (AMR) and growing optimism that gonococcal vaccines are biologically feasible. Evidence suggests serogroup B Neisseria meningitidis vaccines might provide some cross-protection against N. gonorrhoeae, and new gonococcal vaccine candidates based on several approaches are currently in preclinical development. To further stimulate investment and accelerate development of gonococcal vaccines, greater understanding is needed regarding the overall value that gonococcal vaccines might have in addressing public health and societal goals in low-, middle-, and high-income country contexts and how future gonococcal vaccines might be accepted and used, if available. In January 2019, the World Health Organization (WHO) convened a multidisciplinary international group of experts to lay the groundwork for understanding the potential health, economic, and societal value of gonococcal vaccines and their likely acceptance and use, and for developing gonococcal vaccine preferred product characteristics (PPCs). WHO PPCs describe preferences for vaccine attributes that would help optimize vaccine value and use in meeting the global public health need. This paper describes the main discussion points and conclusions from the January 2019 meeting of experts. Participants emphasized the need for vaccines to control N. gonorrhoeae infections with the ultimate goals of preventing adverse sexual and reproductive health outcomes (e.g., infertility) and reducing the impact of gonococcal AMR. Meeting participants also discussed important PPC considerations (e.g., vaccine indications, target populations, and potential immunization strategies) and highlighted crucial research and data needs for guiding the value assessment and PPCs for gonococcal vaccines and advancing gonococcal vaccine development.
dc.description.peerreviewedYes
dc.languageEnglish
dc.language.isoeng
dc.publisherElsevier
dc.relation.ispartofpagefrom4362
dc.relation.ispartofpageto4373
dc.relation.ispartofissue28
dc.relation.ispartofjournalVaccine
dc.relation.ispartofvolume38
dc.subject.fieldofresearchBiological sciences
dc.subject.fieldofresearchAgricultural, veterinary and food sciences
dc.subject.fieldofresearchBiomedical and clinical sciences
dc.subject.fieldofresearchcode31
dc.subject.fieldofresearchcode30
dc.subject.fieldofresearchcode32
dc.subject.keywordsGonococcal vaccines
dc.subject.keywordsGonorrhea
dc.subject.keywordsNeisseria gonorrhoeae
dc.subject.keywordsSexually transmitted infections
dc.subject.keywordsVaccines
dc.titleGonococcal vaccines: Public health value and preferred product characteristics; report of a WHO global stakeholder consultation, January 2019
dc.typeJournal article
dc.type.descriptionC1 - Articles
dcterms.bibliographicCitationGottlieb, SL; Ndowa, F; Hook, EW; Deal, C; Bachmann, L; Abu-Raddad, L; Chen, XS; Jerse, A; Low, N; MacLennan, CA; Petousis-Harris, H; Seib, KL; Unemo, M; Vincent, L; Giersing, BK, Gonococcal vaccines: Public health value and preferred product characteristics; report of a WHO global stakeholder consultation, January 2019, Vaccine, 2020, 38 (28), pp. 4362-4373
dcterms.dateAccepted2020-02-25
dcterms.licensehttp://creativecommons.org/licenses/by/3.0/igo/
dc.date.updated2020-07-17T01:22:00Z
dc.description.versionVersion of Record (VoR)
gro.rights.copyright© 2020 World Health Organization; licensee Elsevier. This is an open access article under the CC BY IGO license (http://creativecommons.org/licenses/by/3.0/igo/), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. You are permitted to remix, transform, and build upon the material for any purpose, even commercially.
gro.hasfulltextFull Text
gro.griffith.authorSeib, Kate


Files in this item

This item appears in the following Collection(s)

  • Journal articles
    Contains articles published by Griffith authors in scholarly journals.

Show simple item record